Simris Group AB OMXSTO:SIMRIS_B:
ANNOUNCES POSITIVE RESULTS FROM ONGOING ANTIBODY-DRUG CONJUGATE (ADC) STUDY WITH NUVISAN
SIMRIS-121 TO PROCEED TO NEXT STAGE OF NUVISAN STUDY
DOSE-ESCALATION IN-VIVO STUDY TO DETERMINE MTD OF ADC IN MICE
Simris Announces Positive Results From Study With Nuvisan
Earlier from Simris
- SIMRIS_B: EBITDA loss narrowed 51% in Q2, but liquidity remains a critical concern
- SIMRIS_B: Revenue plunged, losses narrowed, and urgent funding is needed for continued operations
- SIMRIS_B: Simris Group pivots to biopharma but faces urgent liquidity challenges and going concern risks
- SIMRIS_B: Revenue up, losses narrowed, but urgent funding needed amid leadership and strategic shifts
- SIMRIS_B: EBITDA loss narrowed and new collaborations advanced Simris Group's ADC platform
Later from Simris
- Simris Group Appoints Interim CEO
- SIMRIS_B: Revenue fell sharply and funding is urgent despite operational improvements and R&D progress
- Simris Group Enters Into Bridge Loan Agreement
- Simris Group AB (publ) receives notice of conversion of convertible bonds
- Bulletin from Simris Group AB’s extraordinary general meeting
Follow Simris into a list and get an email when it puts out news.
Follow Simris